The COAST trial[12] revealed that the use of anti-PD-L1 in combination with either oleclumab (anti-CD73) or monalizumab (anti-NGK2A) following concurrent radiotherapy and chemotherapy in unresectable stage III NSCLC led to objective response rate (ORR) and PFS benefits, which holds great significance for conducting further studies with larger sample sizes. Here, CD274 is linked to non-small cell lung carcinoma.